BR0314797A - Derivados da pirimidineamida e o uso dos mesmos - Google Patents

Derivados da pirimidineamida e o uso dos mesmos

Info

Publication number
BR0314797A
BR0314797A BR0314797-5A BR0314797A BR0314797A BR 0314797 A BR0314797 A BR 0314797A BR 0314797 A BR0314797 A BR 0314797A BR 0314797 A BR0314797 A BR 0314797A
Authority
BR
Brazil
Prior art keywords
disease
derivatives
pyrimidineamide
benzoylaminophenyl
pyridyl
Prior art date
Application number
BR0314797-5A
Other languages
English (en)
Inventor
Paul William Manley
Werner Breitenstein
Sandra Jacob
Pascal Furet
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314797(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0314797A publication Critical patent/BR0314797A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

"DERIVADOS DA PIRIMIDINEAMIDA E O USO DOS MESMOS". A presente invenção refere-se a novos derivados da N-(3-benzoilaminofenil)-4-piridil-2-pirimidinamina, processos para a preparação dos mesmos, composições farmacêuticas que contêm os mesmos, o uso dos mesmos de modo opcional em combinação com um ou mais outros compostos ativos de modo farmacêutico para a terapia de uma doença que responda a uma inibição da atividade da proteína cinase, de modo especial uma doença neoplásica, e a um método para o tratamento de uma tal doença.
BR0314797-5A 2002-09-27 2003-09-26 Derivados da pirimidineamida e o uso dos mesmos BR0314797A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds
PCT/EP2003/010724 WO2004029038A1 (en) 2002-09-27 2003-09-26 Novel pyrimidineamide derivatives and the use thereof

Publications (1)

Publication Number Publication Date
BR0314797A true BR0314797A (pt) 2005-07-26

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314797-5A BR0314797A (pt) 2002-09-27 2003-09-26 Derivados da pirimidineamida e o uso dos mesmos

Country Status (24)

Country Link
US (1) US7655669B2 (pt)
EP (1) EP1546127B1 (pt)
JP (2) JP4463685B2 (pt)
KR (2) KR20070098940A (pt)
CN (1) CN100404528C (pt)
AT (1) ATE369355T1 (pt)
AU (1) AU2003270277B2 (pt)
BR (1) BR0314797A (pt)
CA (1) CA2499822C (pt)
DE (1) DE60315479T2 (pt)
DK (1) DK1546127T3 (pt)
EC (1) ECSP055701A (pt)
ES (1) ES2288615T3 (pt)
GB (1) GB0222514D0 (pt)
HK (1) HK1080459A1 (pt)
MX (1) MXPA05003253A (pt)
NO (1) NO20051966L (pt)
NZ (1) NZ538930A (pt)
PL (1) PL374443A1 (pt)
PT (1) PT1546127E (pt)
RU (1) RU2378267C2 (pt)
SI (1) SI1546127T1 (pt)
WO (1) WO2004029038A1 (pt)
ZA (1) ZA200502304B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
NZ553087A (en) 2004-08-31 2010-12-24 Astrazeneca Ab Quinazolinone derivatives and their use as B-raf inhibitors
WO2006027795A1 (en) 2004-09-09 2006-03-16 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
JP5373288B2 (ja) 2005-01-28 2013-12-18 ノバルティス アーゲー Ｔｉｅ−２キナーゼ活性の調節に応答する疾患を処置するためのピリミジルアミノベンズアミドの使用
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
JP5735742B2 (ja) 2006-09-22 2015-06-17 ノバルティス アーゲー Ａｂｌチロシンキナーゼ阻害剤でのフィラデルフィア陽性白血病の処置を最適化する方法
RU2009120882A (ru) * 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
CA2686382C (en) 2007-05-04 2013-09-17 Irm Llc Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
ES2381318T3 (es) * 2007-05-04 2012-05-25 Irm Llc Derivados de pirimidina y composiciones útiles como inhibidores de cinasas C-KIT y PDGFR
EP2152079A4 (en) * 2007-06-04 2011-03-09 Avila Therapeutics Inc HETEROCYCLIC COMPOUNDS AND USES THEREOF
KR101171488B1 (ko) 2007-08-22 2012-08-07 아이알엠 엘엘씨 키나제 억제제로서의 2-헤테로아릴아미노-피리미딘 유도체
CA2697081C (en) 2007-08-22 2013-04-23 Irm Llc 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds and compositions as kinase inhibitors
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
CA2798143A1 (en) * 2010-05-11 2011-12-15 Mahesh Kandula Compound, synthesis, composition and uses thereof
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135699T1 (de) 1986-01-13 1996-04-15 American Cyanamid Co 4,5,6-substituierte 2-pyrimidinamine
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
AU2002342878A1 (en) 2001-05-16 2002-11-25 Axxima Pharmaceuticals Ag Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ATE476686T1 (de) 2003-12-23 2010-08-15 Koninkl Philips Electronics Nv Bestrahlungsverfahren

Also Published As

Publication number Publication date
JP2010043113A (ja) 2010-02-25
PL374443A1 (en) 2005-10-17
NO20051966L (no) 2005-04-22
ZA200502304B (en) 2006-04-26
CA2499822C (en) 2012-04-10
NZ538930A (en) 2008-04-30
ES2288615T3 (es) 2008-01-16
PT1546127E (pt) 2007-11-07
JP4463685B2 (ja) 2010-05-19
JP5178681B2 (ja) 2013-04-10
GB0222514D0 (en) 2002-11-06
RU2378267C2 (ru) 2010-01-10
AU2003270277B2 (en) 2007-08-23
US20060142577A1 (en) 2006-06-29
KR100876055B1 (ko) 2008-12-26
WO2004029038A1 (en) 2004-04-08
AU2003270277A1 (en) 2004-04-19
RU2005113153A (ru) 2006-11-10
DE60315479D1 (de) 2007-09-20
MXPA05003253A (es) 2005-06-08
SI1546127T1 (sl) 2008-08-31
KR20050047128A (ko) 2005-05-19
JP2006508064A (ja) 2006-03-09
DE60315479T2 (de) 2008-04-30
CA2499822A1 (en) 2004-04-08
EP1546127B1 (en) 2007-08-08
ATE369355T1 (de) 2007-08-15
CN1684951A (zh) 2005-10-19
KR20070098940A (ko) 2007-10-05
ECSP055701A (es) 2005-05-30
US7655669B2 (en) 2010-02-02
CN100404528C (zh) 2008-07-23
DK1546127T3 (da) 2007-12-10
EP1546127A1 (en) 2005-06-29
HK1080459A1 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
SE9800836D0 (sv) New Compounds
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
BR0315580A (pt) Derivados de metileno uréia
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
SE0101932D0 (sv) Pharmaceutical combinations
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2273 DE 29/07/2014